facilities_lg06

Dr. Reddy’s, TR-Pharm to collaborate on 3 biosimilars in Turkey

pharmafile | March 11, 2016 | News story | Manufacturing and Production, Medical Communications, Sales and Marketing Dr Reddy's Laboratories, TR-Pharm, biosimilar, generics, marketing collaboration 

Three biosimilar products by the Indian generics company Dr. Reddy’s will be marketed by TR-Pharm in Turkey, the companies said Friday.  

No financial details were disclosed.

The companies, in a joint statement said, TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.

Mehmet Göker, General Manager of TR-Pharm, said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country.”

The partnership will enable Dr. Reddy’s to widen the global footprint of its biosimilar business. The collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region.

M V Ramana, executive vice president & head branded markets (India and Emerging countries), said: “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr. Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”

Anjali Shukla

Related Content

Alvotech and Advanz Pharma announce commercialisation agreement for Eylea biosimilar

Alvotech and Advanz Pharma have announced an exclusive partnership agreement surrounding the supply and commercialisation …

Boan Biotech completes enrolment for phase 3 study of Denosumab

Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative …

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation …

Latest content